Citations 2

Tocilizumab and Satralizumab in MOGAD: Real-world Outcomes for Relapse Prevention (P3-1.002)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000216861

Myelin Alterations Within and Beyond Lesions in MOG Antibody-associated Disease: Insights from Ultra-high field (7T) MRI (S6.002)

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217390